R&D Programs

Clinical Pipeline

Discovery
Preclinical
Phase I
Phase II
MBT-001
Inflammatory Bowel Disease
A helminth-derived recombinant protein with a novel mechanism of action targeting upstream immune dysregulation in IBD. Demonstrates significant protection in colitis models and validated activity against human gut biopsy tissue from IBD patients.
Pre-Clinical
DiscoveryPre-ClinicalPhase IPhase IIPhase III
MBT-002
Inflammatory Bowel Disease
A second distinct helminth-derived protein with a differentiated mechanism of action from MBT-001, providing a complementary approach to immune modulation in IBD. Independently validated in pre-clinical colitis models.
Pre-Clinical
DiscoveryPre-ClinicalPhase IPhase IIPhase III
Platform Programs
Asthma · Rheumatoid Arthritis · Metabolic Disease
The same secretome library that delivered MBT-001 and MBT-002 has demonstrated anti-inflammatory activity across multiple disease models beyond IBD — including asthma, RA, and metabolic syndrome — establishing the platform's broader therapeutic potential.
Discovery
DiscoveryPre-ClinicalPhase IPhase IIPhase III
Near-Term Milestones

What We're Working Toward

MBT-001
IND-enabling studies
Completion of pre-clinical package required for IND/CTA filing and Phase I entry
MBT-002
Lead candidate confirmation
Advanced pre-clinical validation and candidate selection for development track
Platform
Expansion screen
Screening of additional secretome hits against asthma, RA, and metabolic disease models